Filing Analysis
agilon health, inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The report was filed and the press release issued on May 6, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- The report was signed by Jeffrey Schwaneke, Chief Financial Officer.
agilon health, inc. has appointed Tim O'Rourke as its new Chief Executive Officer and President, effective May 7, 2026. Mr. O'Rourke, a veteran of Humana and Centene, succeeds the previous leadership and will also join the Board of Directors.
Key Facts
- Tim O'Rourke appointed CEO and President effective May 7, 2026.
- Compensation includes a base salary of $850,000 and a 100% target annual bonus.
- One-time cash signing bonus of $500,000 provided, subject to a one-year clawback.
- Equity incentives include 120,000 RSUs and 200,000 PSUs.
- PSU vesting is tied to aggressive 30-day weighted average stock price targets of $50, $100, and $150.
- Mr. O'Rourke previously served as President of Help at Home, LLC and held senior roles at Humana, Inc. for 23 years.
agilon health, inc. has implemented a 1-for-25 reverse stock split of its common stock, effective March 30, 2026. The company's common stock will begin trading on a split-adjusted basis on the New York Stock Exchange at the market open on March 31, 2026.
Red Flags
- A 1-for-25 reverse stock split is a significant consolidation, often utilized by companies to artificially inflate share price to maintain exchange listing requirements.
Key Facts
- The reverse stock split ratio is 1-for-25.
- The split was effective at 4:36 p.m. Eastern Time on March 30, 2026.
- Stockholders approved the amendment at a special meeting held on March 17, 2026.
- No fractional shares will be issued; stockholders will receive cash in lieu of fractional shares.
- The new CUSIP number for the common stock is 00857U 206.
- The number of authorized shares and the par value of $0.01 per share remain unchanged.
agilon health stockholders approved a reverse stock split at a special meeting on March 17, 2026. The Board of Directors subsequently selected a 1-for-25 ratio, with the split scheduled to take effect on March 30, 2026.
Red Flags
- Significant 1-for-25 reverse stock split ratio, often indicating a struggle to maintain minimum bid price requirements.
- The company is not reducing the number of authorized shares, which significantly increases the capacity for future equity dilution.
- The need for a special meeting specifically for a reverse split suggests urgent regulatory or listing compliance issues.
Key Facts
- Stockholders approved a reverse split ratio range of 1-for-5 to 1-for-25 on March 17, 2026.
- The Board of Directors finalized the ratio at the maximum 1-for-25 on March 18, 2026.
- The split is effective March 30, 2026, at 5:00 p.m. Eastern Time.
- The number of authorized shares of common stock will not be reduced following the split.
- The proposal passed with 356,574,789 votes in favor versus 6,187,388 against.
agilon health, inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The company furnished a press release and an investor presentation as part of the disclosure.
Key Facts
- Financial results for the three and twelve months ended December 31, 2025, were released on February 25, 2026.
- The company furnished Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
- The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).